文献速递腹部CT

利用胰腺CT评估可切除胰腺导管腺癌患者 upfront 术后复发:风险评分的开发与验证

Estimating Recurrence after Upfront Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma by Using Pancreatic CT: Development and Validation of a Risk Score.
PubMed 文献 · Radiology · 2020-07-14

本研究为回顾性研究,开发集262例、测试集133例可切除胰腺导管腺癌患者接受 upfront 手术。基于肿瘤大小、门静脉期低密度、肿瘤坏死、胰周浸润和可疑转移淋巴结构建术前风险评分,测试集C指数0.68优于病理T分期0.60。

要点

  • 肿瘤坏死(HR 2.04)、可疑转移淋巴结(HR 1.94)、门静脉期低密度(HR 1.66)、胰周浸润(HR 1.50)和肿瘤大小(HR 1.23)为独立预测因素。
  • 风险评分将患者分为预后良好、中等和差三组,1年无复发生存率分别为0.87、0.58和0.26。
  • 测试集C指数0.68(95%CI 0.63-0.74)优于病理T分期0.60(95%CI 0.55-0.66),P=0.03。

关键影像表现/征象

  • 门静脉期低密度肿瘤与复发或死亡风险独立相关(HR 1.66;95%CI 1.01, 2.73;P=0.04)。
  • 肿瘤坏死与复发或死亡风险独立相关(HR 2.04;95%CI 1.38, 3.03;P<0.001)。
  • 胰周肿瘤浸润与复发或死亡风险独立相关(HR 1.50;95%CI 1.07, 2.11;P=0.02)。
  • 可疑转移淋巴结与复发或死亡风险独立相关(HR 1.94;95%CI 1.38, 2.72;P<0.001)。

诊断标准与关键数值

  • 风险评分包含五个独立变量:肿瘤大小(HR 1.23;95%CI 1.05, 1.44;P=0.009)、门静脉期低密度肿瘤(HR 1.66;95%CI 1.01, 2.73;P=0.04)、肿瘤坏死(HR 2.04;95%CI 1.38, 3.03;P<0.001)、胰周肿瘤浸润(HR 1.50;95%CI 1.07, 2.11;P=0.02)和可疑转移淋巴结(HR 1.94;95%CI 1.38, 2.72;P<0.001)。
  • 测试集风险评分的C指数为0.68(95%CI 0.63, 0.74),病理T分期的C指数为0.60(95%CI 0.55, 0.66),两者比较P=0.03。
  • 风险评分将患者分为预后良好、中等和差三组,1年无复发生存率分别为0.87、0.58和0.26。

临床应用与阅片要点

  • 术前可依据肿瘤大小、门静脉期低密度、肿瘤坏死、胰周浸润和可疑转移淋巴结计算风险评分,辅助预测无复发生存。
  • 风险评分在测试集中区分能力优于病理T分期(C指数0.68 vs 0.60,P=0.03)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background No preoperative model is available for predicting postsurgical prognosis of patients with resectable pancreatic ductal adenocarcinoma (PDAC). Purpose To develop and validate a preoperative risk scoring system using clinical and CT variables to predict recurrence-free survival (RFS) after upfront surgery in patients with resectable PDAC. Materials and Methods In this retrospective study, consecutive patients with resectable PDAC underwent upfront surgery from January 2014 to December 2015 (development set) and from January 2016 to January 2017 (test set). In the development set, multivariable Cox proportional hazard modeling with bootstrapping was used to select clinical and CT variables associated with RFS and to construct a risk scoring system. The discrimination capability of the risk score was assessed by using the Harrell C-index and compared with that of pathologic American Joint Committee on Cancer tumor stage. The risk score was validated in the test set. Results A total of 395 patients were evaluated, including 262 patients (mean age ± standard deviation, 64 years ± 10; 155 men) in the development set and 133 (mean age, 64 years ± 9; 79 men) in the test set. Five independent variables predicted risk of recurrence or death: tumor size (hazard ratio [HR], 1.23; 95% confidence interval [CI]: 1.05, 1.44; P = .009), hypodense tumor in the portal venous phase (HR, 1.66; 95% CI: 1.01, 2.73; P = .04), tumor necrosis (HR, 2.04; 95% CI: 1.38, 3.03; P < .001), peripancreatic tumor infiltration (HR, 1.50; 95% CI: 1.07, 2.11; P = .02), and suspicious metastatic lymph nodes (HR, 1.94; 95% CI: 1.38, 2.72; P < .001). In the test set, the risk score showed good discrimination capability (C-index of 0.68; 95% CI: 0.63, 0.74) and outperformed the pathologic tumor stage (C-index of 0.60; 95% CI: 0.55, 0.66; P = .03). Patients were categorized into favorable, intermediate, and poor prognosis groups with 1-year RFS of 0.87, 0.58, and 0.26, respectively. Conclusion The presented preoperative risk score can predict recurrence-free survival after upfront surgery in patients with resectable pancreatic ductal adenocarcinoma. © RSNA, 2020 Online supplemental material is available for this article. See also the editorial by Pandharipande and Anderson in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Kim DW, Lee SS, Kim SO, et al. Estimating Recurrence after Upfront Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma by Using Pancreatic CT: Development and Validation of a Risk Score. Radiology. 2020. PMID: 32662759. doi:10.1148/radiol.2020200281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。